ANI PHARMACEUTICALS INC

ANIP

ANI PHARMACEUTICALS INC

ANIP

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):150,469

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:22,666,453Shares Outstanding:20,914,000Institutional Ownership Pct.:108.38%

Earnings Market Reaction:

Filing Date:2026-08-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	360	311	286	263	218	150	145	145	240	229	221	193
Restricted Cash Current	0	0	0	0	0	0	0	0	-	-	0	0
Accounts Receivable Net Current	274	255	281	253	226	220	222	196	166	172	162	179
Inventory Net	143	143	143	146	138	137	137	148	125	114	111	107
Assets Held For Sale Not Part Of Disposal Group Cu…	-	-	-	-	-	-	0	0	0	0	8	8
Prepaid Expense Current	32	22	23	19	15	23	18	17	14	16	17	11
Equity Securities Fv Ni Cost	16	15	9	9	6	5	6	8	7	10	0	-
Assets Current	825	747	753	698	603	536	528	521	555	541	520	497
Assets Noncurrent
Property Plant And Equipment Net	73	67	62	64	59	58	57	57	52	49	45	44
Deferred Income Tax Assets Net	71	67	69	71	92	88	85	68	90	88	91	84
Intangible Assets Net Excluding Goodwill	450	467	480	500	520	538	542	570	183	196	209	220
Goodwill	62	62	62	62	61	61	60	60	28	28	28	28
Other Assets Noncurrent	12	12	14	12	8	10	12	11	13	14	12	16
Assets	1,494	1,422	1,440	1,408	1,343	1,292	1,284	1,287	921	915	904	890
Liabilities And Stockhold…
Liabilities Current
Long Term Debt Current	21	19	17	15	13	11	9	7	1	1	1	1
Accounts Payable Current	74	70	63	70	55	53	46	61	49	49	37	34
Accrued Royalties Current	56	34	48	51	36	24	23	23	20	15	16	12
Employee Related Liabilities Current	27	16	38	33	33	22	38	30	16	10	24	15
Taxes Payable Current	4	5	1	0	3	14	6	0	0	11	8	1
Business Combination Contingent Consideration Liab…	-	-	0	0	0	0	0	1	1	0	12	24
Accrued Liabilities Current	17	14	17	14	15	12	14	18	7	7	6	5
Liabilities Current	284	240	278	271	237	202	194	190	140	137	145	134
Long Term Debt Noncurrent
Long Term Debt Noncurrent	280	286	292	298	301	305	309	313	284	285	285	285
Business Combination Contingent Consideration Liab…	9	9	10	11	18	17	20	20	11	11	12	11
Other Liabilities Noncurrent	16	16	12	11	7	7	6	7	5	5	5	5
Liabilities	897	860	900	902	881	849	856	857	440	438	447	435
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity
Temporary Equity Carrying Amount Attributable To P…	-	-	0	0	25	25	25	25	25	25	25	25
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Value	-54	-53	-33	-33	-32	-31	-21	-21	-20	-19	-10	-10
Additional Paid In Capital	620	608	596	586	542	531	520	511	532	524	514	507
Retained Earnings Accumulated Deficit	31	6	-23	-51	-77	-85	-100	-90	-65	-62	-80	-81
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	1	3	3	4	5	5	8	9	9	14
Stockholders Equity	597	562	541	506	437	419	404	406	456	452	433	430
Liabilities And Stockholders Equity	1,494	1,422	1,440	1,408	1,343	1,292	1,284	1,287	921	915	904	890
Convertible Preferred Stock	-	-	0	0	0	0	0	0	0	25	0	0
Common Stock	-	23	0	-11	33	0	0	0	0	0	0	0
Class C Special Stock	-	0	0	0	0	0	0	0	0	0	0	0
Valuation Allowances And Reserves Balance	-	-	172	125	120	140	128	91	103	92	97	98
Temporary Equity Shares Outstanding	-	-	-	-	-	-	0	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	-	-	0	-	-	-	0	-	-	-	-	-
Common Stock Shares Authorized	-	-	66	-	-	-	33	-	-	-	-	-
Common Stock Shares Issued	-	-	23	-	-	-	22	-	-	-	-	-
Shares Outstanding	-	-	22	-	-	-	21	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	2	2	2	2	2	2	2	2	2	2	2	2
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Shares	1	1	1	1	1	1	0	0	0	0	0	0

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-4.09%	3.23%	-5.14%	-	-	-	-	-	-	-	-	-
2025	-11.43%	-1.21%	1.78%	14.75%	14.20%	15.66%	-6.17%	-8.87%	-8.23%	1.04%	9.50%	5.56%
2024	-4.63%	-6.42%	-7.05%	0.73%	-7.13%	-7.85%	-6.85%	-11.44%	-4.56%	3.83%	11.83%	-3.07%
2023	-	-	-	5.73%	-4.94%	-3.60%	-6.90%	1.51%	0.59%	2.82%	-3.24%	-9.22%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.91	3.12	2.71	2.58	2.54	2.66	2.72	2.74	3.97	3.95	3.57	3.70
Quick Ratio	2.29	2.43	2.11	1.97	1.90	1.86	1.92	1.87	2.97	3.00	2.69	2.83
Working Capital	541.78M	507.57M	475.01M	427.85M	365.80M	334.48M	334.00M	331.36M	415.48M	403.67M	374.34M	362.87M
Leverage & Debt
Debt to Equity	1.50	1.53	1.66	1.78	2.02	2.03	2.12	2.11	0.97	0.97	1.03	1.01
Interest Coverage TTM	9.09	6.75	5.54	3.32	0.79	0.35	0.03	0.67	2.34	2.41	1.74	1.47
Debt Ratio	0.60	0.60	0.62	0.64	0.66	0.66	0.67	0.67	0.48	0.48	0.49	0.49
Efficiency & Turnover
Asset Turnover TTM	0.69	0.68	0.65	0.61	0.66	0.61	0.56	0.51	0.61	0.62	0.58	0.55
Days Sales Outstanding TTM	93.29	94.00	103.88	99.09	95.66	106.34	114.01	123.28	114.80	122.43	122.78	129.66
Receivables Turnover TTM	3.91	3.88	3.51	3.68	3.82	3.43	3.20	2.96	3.18	2.98	2.97	2.82
Per Share Metrics
Diluted EPS TTM	4.83	4.24	3.64	1.94	-0.50	-1.05	-0.96	-0.39	1.40	1.81	1.03	0.66
Free Cash Flow Per Share TTM	8.18	9.14	8.55	7.76	6.32	3.40	2.47	3.96	5.15	5.48	6.12	3.18
Dividend Per Share TTM	0.04	0.04	0.06	0.06	0.06	0.08	0.08	0.08	0.08	0.09	0.09	0.09
Margin Metrics
Gross Profit Margin TTM	60.40%	60.83%	61.36%	61.14%	61.06%	59.34%	59.27%	59.79%	61.34%	62.71%	62.71%	63.41%
Operating Profit Margin TTM	15.37%	13.40%	12.58%	8.70%	2.03%	0.96%	0.10%	2.10%	9.31%	11.09%	9.65%	9.36%
Net Profit Margin TTM	10.82%	9.89%	8.74%	4.96%	-1.37%	-3.12%	-3.01%	-1.35%	5.01%	6.79%	3.86%	2.80%
Growth Metrics
Net Revenue Growth (1Y)	30.90%	37.03%	43.78%	48.87%	38.68%	30.26%	26.20%	23.60%	34.27%	44.26%	53.87%	58.75%
Net Income Growth (1Y)	-1,136.51%	-534.23%	-516.69%	-646.65%	-137.80%	-159.90%	-198.63%	-159.65%	-523.51%	-227.57%	-137.92%	-118.21%
EPS Growth (1Y)	-1,071.64%	-507.09%	-501.42%	-628.41%	-136.82%	-158.34%	-191.91%	-158.05%	-487.72%	-209.49%	-134.25%	-115.72%
Valuation Metrics
P/E TTM	16.55	17.60	20.51	44.87	-126.73	-62.37	-57.66	-154.43	45.54	37.57	52.86	87.24
P/B TTM	2.93	2.86	2.93	3.64	2.96	3.14	2.65	2.85	2.70	2.92	2.29	2.55
P/S TTM	1.79	1.74	1.79	2.22	1.73	1.95	1.74	2.08	2.28	2.55	2.04	2.44
Market Cap	1.75B	1.61B	1.58B	1.84B	1.29B	1.31B	1.07B	1.16B	1.23B	1.32B	992.58M	1.10B
Enterprise Value	1.69B	1.60B	1.61B	1.89B	1.39B	1.48B	1.24B	1.33B	1.28B	1.38B	1.06B	1.19B
Calculated Values
Free Cash Flow TTM	172.99M	191.17M	171.39M	155.73M	125.44M	66.61M	47.78M	76.78M	99.54M	104.70M	110.09M	60.09M
Net Debt	-58.76M	-5.92M	23.49M	50.27M	96.87M	166.65M	173.42M	175.05M	45.13M	56.86M	64.55M	92.80M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2026-06-29Sale

Owner: Carey, Stephen P.

Title: SVP & CFO

Shares: 2,850

Price/Share: $84.12

Value: $239,742.00

Shares Owned: 177,543

Relationship: Officer

Ownership: Direct

2026-06-12Sale

Owner: Cook, Meredith

Title: SR. VP, GENERAL COUNSEL & SEC.

Shares: 500

Price/Share: $82.03

Value: $41,015.00

Shares Owned: 77,890

Relationship: Officer

Ownership: Direct

2026-06-08Sale

Owner: Haughey, Thomas

Title: -

Shares: 2,000

Price/Share: $80.88

Value: $161,760.00

Shares Owned: 38,878

Relationship: Director

Ownership: Direct

2026-06-05Sale

Owner: Carey, Stephen P.

Title: SVP & CFO

Shares: 3,312

Price/Share: $80.00

Value: $264,960.00

Shares Owned: 180,393

Relationship: Officer

Ownership: Direct

2026-05-13Sale

Owner: Walsh, Patrick D

Title: -

Shares: 10,000

Price/Share: $80.63

Value: $806,300.00

Shares Owned: 38,432

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	2,850	84.12	$239,742.00	177,543	4
2026-06-12	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	500	82.03	$41,015.00	77,890	4
2026-06-08	Haughey, Thomas	Director	-	Direct	Sale	2,000	80.88	$161,760.00	38,878	4
2026-06-05	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	3,312	80.00	$264,960.00	180,393	4
2026-05-13	Walsh, Patrick D	Director	-	Direct	Sale	10,000	80.63	$806,300.00	38,432	4
2026-05-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	500	78.16	$39,080.00	78,390	4
2026-05-12	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	2,772	79.50	$220,374.00	78,696	4
2026-05-12	Rowland, Thomas Andrew	Officer	SVP, HEAD - ESTABLISHED BRANDS	Direct	Sale	459	79.21	$36,357.39	38,271	4
2026-05-11	Lalwani, Nikhil	Director,Officer	PRESIDENT & CEO	Direct	Sale	55,000	77.57	$4,266,350.00	349,889	4
2026-04-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	500	77.95	$38,975.00	78,890	4
2026-03-13	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	3,162	71.64	$226,525.68	91,309	4
2026-03-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	500	72.62	$36,310.00	79,390	4
2026-03-11	Rowland, Thomas Andrew	Officer	SVP, HEAD - ESTABLISHED BRANDS	Direct	Sale	4,772	74.91	$357,470.52	38,730	4
2026-03-09	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	3,602	74.18	$267,196.36	94,471	4
2026-03-09	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	5,087	74.13	$377,099.31	51,946	4
2026-03-05	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	7,312	75.49	$551,982.88	185,543	4
2026-03-03	Walsh, Patrick D	Director	-	Direct	Sale	6,000	74.23	$445,380.00	52,405	4
2026-03-03	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	2,060	76.50	$157,590.00	84,782	4
2026-03-02	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	417	74.00	$30,858.00	103,508	4
2026-02-20	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,730	77.99	$134,922.70	49,263	4
2026-02-20	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	5,323	78.02	$415,300.46	84,840	4
2026-02-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	500	76.80	$38,400.00	69,329	4
2026-02-12	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	7,032	76.55	$538,299.60	92,566	4
2026-01-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	500	84.33	$42,165.00	74,374	4
2025-12-18	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,622	82.40	$133,652.80	58,564	4
2025-12-12	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	82.32	$32,928.00	74,874	4
2025-12-05	Tannenbaum, Renee P	Director	-	Direct	Sale	1,800	81.15	$146,070.00	25,157	4
2025-11-13	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	94	88.00	$8,272.00	158,490	4
2025-11-13	Walsh, Patrick D	Director	-	Direct	Sale	8,643	86.88	$750,903.84	61,405	4
2025-11-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	87.27	$34,908.00	75,274	4
2025-10-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	90.09	$36,036.00	75,674	4
2025-09-19	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,000	98.04	$98,040.00	60,186	4
2025-09-12	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	98.42	$39,368.00	76,074	4
2025-09-03	Pera, Antonio R	Director	-	Direct	Sale	7,292	94.94	$692,302.48	22,660	4
2025-08-25	Leonard, Matthew J	Director	-	Direct	Sale	2,528	90.62	$229,087.36	6,864	4
2025-08-22	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,763	91.10	$160,609.30	62,896	4
2025-08-21	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	52,988	90.44	$4,792,234.72	431,920	4
2025-08-20	Pera, Antonio R	Director	-	Direct	Sale	5,421	89.73	$486,426.33	29,952	4
2025-08-18	Thoma, Jeanne	Director	-	Direct	Sale	21,540	89.32	$1,923,952.80	23,405	4
2025-08-18	Leonard, Matthew J	Director	-	Direct	Sale	6,937	88.17	$611,635.29	9,392	4
2025-08-15	Walsh, Patrick D	Director	-	Direct	Sale	9,000	89.05	$801,450.00	70,048	4
2025-08-15	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	86.97	$1,739,400.00	173,226	4
2025-08-15	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	52,990	87.15	$4,618,078.50	531,920	4
2025-08-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	88.87	$35,548.00	76,474	4
2025-08-12	Lalwani, Nikhil	Director,Officer	PRESIDENT & CEO	Direct	Sale	56,960	85.93	$4,894,572.80	411,219	4
2025-08-12	Haughey, Thomas	Director	-	Direct	Sale	19,341	85.93	$1,661,972.13	36,521	4
2025-08-12	Rowland, Thomas Andrew	Officer	SVP, HEAD - ESTABLISHED BRANDS	Direct	Sale	4,975	85.71	$426,407.25	40,794	4
2025-08-12	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	50,000	86.07	$4,303,500.00	180,863	4
2025-08-12	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	5,873	86.53	$508,190.69	84,024	4
2025-07-14	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	64.88	$25,952.00	78,945	4
2025-06-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	61.37	$24,548.00	79,345	4
2025-05-15	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	881	60.07	$52,921.67	89,897	4
2025-05-14	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	4,000	60.45	$241,800.00	107,317	4
2025-05-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	62.20	$24,880.00	79,745	4
2025-05-09	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	700	76.83	$53,781.00	631,920	4
2025-04-14	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	68.96	$27,584.00	80,145	4
2025-03-19	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,866	65.00	$121,290.00	64,659	4
2025-03-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	63.33	$25,332.00	80,545	4
2025-03-07	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,000	60.86	$60,860.00	66,525	4
2025-03-05	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	5,384	60.02	$323,147.68	94,092	4
2025-02-21	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,000	60.20	$60,200.00	68,624	4
2025-02-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	59.54	$23,816.00	83,478	4
2025-01-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	400	53.92	$21,568.00	55,588	4
2024-12-17	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	7,500	55.79	$418,425.00	154,468	4
2024-12-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	56.24	$14,060.00	55,988	4
2024-12-11	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	1,000	60.00	$60,000.00	49,059	4
2024-11-26	Lalwani, Nikhil	Director,Officer	PRESIDENT & CEO	Direct	Sale	33,481	58.12	$1,945,915.72	370,378	4
2024-11-15	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	6,500	57.70	$375,050.00	76,777	4
2024-11-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	61.36	$15,340.00	56,238	4
2024-10-14	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	57.19	$14,297.50	56,488	4
2024-09-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	56.82	$14,205.00	56,738	4
2024-08-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	59.62	$14,905.00	56,988	4
2024-07-18	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	2,743	62.00	$170,066.00	632,620	4
2024-07-17	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	14,257	63.16	$900,472.12	635,363	4
2024-07-12	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	64.91	$16,227.50	58,981	4
2024-07-01	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	63.44	$1,268,800.00	193,226	4
2024-06-21	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	20,000	58.90	$1,178,000.00	682,620	4
2024-06-20	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	11,447	59.86	$685,217.42	702,620	4
2024-06-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	63.80	$15,950.00	59,231	4
2024-06-05	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	2,985	67.00	$199,995.00	77,227	4
2024-06-04	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	5,000	63.58	$317,900.00	161,968	4
2024-06-03	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	64.41	$1,288,200.00	213,226	4
2024-05-21	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	2,000	61.61	$123,220.00	83,277	4
2024-05-20	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	12,855	61.81	$794,567.55	732,620	4
2024-05-17	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	5,836	62.09	$362,357.24	745,475	4
2024-05-16	Tannenbaum, Renee P	Director	-	Direct	Sale	2,000	63.87	$127,740.00	18,211	4
2024-05-14	Lalwani, Nikhil	Director,Officer	PRESIDENT & CEO	Direct	Sale	16,669	66.10	$1,101,820.90	377,505	4
2024-05-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	67.69	$16,922.50	59,481	4
2024-05-01	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	66.62	$1,332,400.00	233,226	4
2024-04-19	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	16,809	65.17	$1,095,442.53	782,620	4
2024-04-17	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	9,520	65.40	$622,608.00	809,852	4
2024-04-12	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	67.79	$16,947.50	59,731	4
2024-04-01	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	67.25	$1,345,000.00	253,226	4
2024-03-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	66.54	$16,635.00	59,981	4
2024-03-11	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	65.81	$1,316,200.00	273,226	4
2024-03-11	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	7,787	65.55	$510,437.85	177,712	4
2024-03-08	Lalwani, Nikhil	Director,Officer	PRESIDENT & CEO	Direct	Sale	16,292	67.13	$1,093,681.96	411,629	4
2024-03-08	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	10,000	67.17	$671,700.00	832,620	4
2024-03-07	Marken, James G.	Officer	SVP OPS & PROD DEV	Direct	Sale	24,338	66.37	$1,615,313.06	124,492	4
2024-03-07	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	15,085	66.35	$1,000,889.75	842,620	4
2024-03-05	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	5,000	66.00	$330,000.00	87,387	4
2024-03-04	Pera, Antonio R	Director	-	Direct	Sale	7,000	65.20	$456,400.00	26,627	4
2024-02-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	56.04	$14,010.00	36,799	4
2024-01-23	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	15,000	56.44	$846,600.00	882,620	4
2024-01-18	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	9,784	55.30	$541,055.20	907,836	4
2024-01-12	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	56.43	$14,107.50	37,049	4
2023-12-19	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	25,000	52.65	$1,316,250.00	932,620	4
2023-12-11	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	49.21	$12,302.50	37,299	4
2023-11-17	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	13,000	51.00	$663,000.00	982,620	4
2023-11-16	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	6,448	51.66	$333,103.68	995,620	4/A
2023-11-15	Davis, Krista	Officer	SVP, CHIEF HR OFFICER	Direct	Sale	2,622	53.81	$141,089.82	32,587	4
2023-11-13	Cook, Meredith	Officer	SR. VP, GENERAL COUNSEL & SEC.	Direct	Sale	250	52.03	$13,007.50	37,549	4
2023-11-10	Mutz, Christopher	Officer	HEAD OF RARE DISEASE	Direct	Sale	3,000	52.47	$157,410.00	63,607	4
2023-10-19	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	10,000	57.06	$570,600.00	1,032,620	4
2023-10-16	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	13,063	58.31	$761,703.53	1,057,620	4
2023-10-02	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	56.48	$1,129,600.00	293,226	4
2023-09-19	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	25,333	61.23	$1,551,139.59	1,082,620	4
2023-09-01	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	64.70	$1,294,000.00	313,226	4
2023-08-29	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	25,000	63.37	$1,584,250.00	1,132,620	4
2023-08-23	Gutwerg, Ori	Officer	SVP, GENERICS	Direct	Sale	15,561	62.39	$970,850.79	60,915	4
2023-08-23	Marken, James G.	Officer	SVP OPS & PROD DEV	Direct	Sale	3,932	63.00	$247,716.00	133,112	4
2023-08-16	Meridian, Venture Partner…	TenPercentOwner	-	Direct	Sale	200,000	58.50	$11,700,000.00	1,819,259	4
2023-08-15	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	22,110	61.60	$1,361,976.00	1,182,620	4
2023-08-15	Lalwani, Nikhil	Director,Officer	PRESIDENT & CEO	Direct	Sale	11,616	61.13	$710,086.08	353,390	4
2023-08-14	Pera, Antonio R	Director	-	Direct	Sale	3,000	60.37	$181,110.00	33,627	4
2023-08-14	Carey, Stephen P.	Officer	SVP & CFO	Direct	Sale	17,639	61.37	$1,082,505.43	155,839	4
2023-08-01	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	51.06	$1,021,200.00	333,226	4
2023-07-21	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	11,500	52.56	$604,440.00	1,232,620	4
2023-07-18	Shanmugam, Muthusamy	Director,Officer	HEAD OF R&D, COO-NOVITIUM OPS	Indirect	Sale	6,700	51.84	$347,328.00	1,256,089	4
2023-07-03	Gassert, Chad	Officer	SVP - CORP. DEV. & STRATEGY	Indirect	Sale	20,000	53.43	$1,068,600.00	353,226	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Institutional Ownership

No data available for chart

2026-03-31

108.38%

Inst. Shares: 22,666,453

Shares Outstanding: 20,914,000

2025-12-31

102.76%

Inst. Shares: 20,606,907

Shares Outstanding: 20,053,000

2025-09-30

99.52%

Inst. Shares: 19,977,955

Shares Outstanding: 20,074,000

2025-06-30

97.08%

Inst. Shares: 19,254,935

Shares Outstanding: 19,834,000

2025-03-31

97.75%

Inst. Shares: 19,165,195

Shares Outstanding: 19,607,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	22,666,453	20,914,000	108.38%
2025-12-31	20,606,907	20,053,000	102.76%
2025-09-30	19,977,955	20,074,000	99.52%
2025-06-30	19,254,935	19,834,000	97.08%
2025-03-31	19,165,195	19,607,000	97.75%
2024-12-31	18,388,447	19,318,000	95.19%
2024-09-30	18,142,701	19,404,000	93.50%
2024-06-30	14,497,283	19,321,000	75.03%
2024-03-31	13,331,428	19,099,000	69.80%
2023-12-31	12,820,057	18,001,000	71.22%
2023-09-30	12,472,455	18,883,000	66.05%
2023-06-30	11,401,819	17,688,000	64.46%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ANI PHARMACEUTICALS INC (ANIP) — SEC Financial Statements & Analysis

ANI PHARMACEUTICALS INC (ANIP) is a pharmaceutical preparations company, incorporated in DE. ANI PHARMACEUTICALS INC trades on Nasdaq as: ANIP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ANI PHARMACEUTICALS INC reported a 30.90% year-over-year revenue growth, a Gross Profit Margin of 60.40% (TTM), a Debt-to-Equity ratio of 1.50x, a Price-to-Sales (P/S) ratio of 1.79x (TTM), a Price-to-Book (P/B) ratio of 2.93x (TTM), at a market cap of $1.75B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 30.90%
Gross Profit Margin TTM: 60.40%
Debt To Equity: 1.50x
P/S TTM: 1.79x
P/B TTM: 2.93x
Market Cap: $1.75B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ANI PHARMACEUTICALS INC in?

ANI PHARMACEUTICALS INC (ANIP) operates in the Pharmaceutical Preparations industry.

What is ANIP's market cap?

ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of $1.75B as of 2026-06-30.

What is ANIP's P/E ratio?

ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month P/E ratio is 16.55x as of 2026-06-30.

What exchange does ANIP trade on?

ANI PHARMACEUTICALS INC (ANIP) trades on the Nasdaq.

Where is ANI PHARMACEUTICALS INC incorporated?

ANI PHARMACEUTICALS INC is incorporated in DE.